The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

abstract Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …

Background Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic
polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response …

Background According to current consensus guidelines for type 2 diabetes management,
bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single …

Background Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose
and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy …

Gut hormones orchestrate pivotal physiological processes in multiple metabolically active
tissues, including the pancreas, liver, adipose tissue, gut and central nervous system …

Long-acting analogues of the naturally occurring incretin, glucagon-like peptide-1 (GLP-1)
and those modified to interact also with receptors for glucose-dependent insulinotropic …

The discovery and development of so-called gut hormone co-agonists as a new class of
drugs for the treatment of diabetes and obesity is considered a transformative breakthrough …

The peptide hormone glucagon, discovered in late 1922, is secreted from pancreatic alpha
cells and is an essential regulator of metabolic homeostasis. This review summarises …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical
therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to …